Shingrix mas efectiva que Zostavax

Recombinant Zoster Vaccine More Efficacious Than Live Vaccine

By Amy Orciari Herman

Edited by André Sofair, MD, MPH, and William E. Chavey, MD, MS

The adjuvant recombinant subunit herpes zoster vaccine (Shingrix) seems to prevent more zoster cases than the live attenuated vaccine (Zostavax) — but may also cause more injection site reactions — according to a network meta-analysis in The BMJ.

Researchers examined data from 22 trials examining the efficacy of the vaccines in adults aged 50 and older. Among the findings:

• For preventing confirmed zoster infection, the recombinant vaccine was more efficacious than the live vaccine or placebo, whereas there was no difference between the live vaccine and placebo. 
• For suspected zoster, the recombinant vaccine was again more efficacious than the live vaccine or placebo, and the live vaccine was superior to placebo.
• Both vaccines were superior to placebo for preventing postherpetic neuralgia.
• Injection site reactions were more common with the recombinant vaccine than with the live vaccine.
• Serious adverse events did not differ across the groups.

The CDC currently recommends the recombinant vaccine over the live vaccine for healthy adults aged 50 and older.

The BMJ article (Free)

Background: NEJM Journal Watch General Medicine coverage of CDC's 2018 adult immunization schedule (featuring zoster recommendations)(Free)

Sent from my iPhone

Benjamin Hidalgo-Matlock
Skin Care Physicians of Costa Rica

Clinica Victoria en San Pedro: 2224-0654
Momentum Escazu: 2101-9574

Please excuse the shortness of this message, as it has been sent from
a mobile device.